1. Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
- Author
-
Liana Cuccia, L. Gulino, Michele Santodirocco, Vincenzo Caruso, Vincenzo Positano, Aldo Filosa, Maria Antonietta Romeo, Paolo Ricchi, Saveria Campisi, Massimiliano Missere, Angelo Peluso, Maria Caterina Putti, Alessia Pepe, Lorella Pitrolo, Giuseppe Rossi, Paolo Cianciulli, Massimo Midiri, Massimo Lombardi, Antonella Meloni, Giuseppe D'Ascola, Pepe, A, Meloni, A, Rossi, G, Cuccia, L, D'Ascola, G, Santodirocco, M, Cianciulli, P, Caruso, V, Romeo, M, Filosa, A, Pitrolo, L, Putti, M, Peluso, A, Campisi, S, Missere, M, Midiri, M, Gulino, L, Positano, V, Lombardi, M, and Ricchi, P
- Subjects
Male ,Liver Iron Concentration ,Time Factors ,Thalassemia ,Ventricular Function, Left ,chemistry.chemical_compound ,Medicine ,Deferiprone ,Prospective Studies ,Medicine(all) ,Ejection fraction ,Radiological and Ultrasound Technology ,Beta thalassemia ,Deferoxamine ,Treatment Outcome ,Italy ,Liver ,Cardiology ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,Cardiomyopathies ,medicine.drug ,Adult ,medicine.medical_specialty ,Combination therapy ,Pyridones ,Chelation therapy ,Magnetic Resonance Imaging, Cine ,Iron Chelating Agents ,Young Adult ,Predictive Value of Tests ,Internal medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Analysis of Variance ,Chi-Square Distribution ,business.industry ,Research ,Myocardium ,beta-Thalassemia ,Stroke Volume ,medicine.disease ,Surgery ,chemistry ,Ventricular Function, Right ,Cardiovascular magnetic resonance ,business - Abstract
Background: Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months. Methods: Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74) monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images. Results: The percentage of patients that maintained a normal global heart T2* value was comparable between DFP+DFO versus both monotherapy groups. Among the patients with myocardial iron overload at baseline, the changes in the global heart T2* and in biventricular function were not significantly different in DFP+DFO compared with the DFP group. The improvement in the global heart T2* was significantly higher in the DFP+DFO than the DFO group, without a difference in biventricular function. Among the patients with hepatic iron at baseline, the decrease in liver iron concentration values was significantly higher with combination therapy than with either monotherapy group. Conclusions: In TM patients at the dosages used in the real world, the combined DFP+DFO regimen was more effective in removing cardiac iron than DFO, and was superior in clearing hepatic iron than either DFO or DFP monotherapy. Combined therapy did not show an additional effect on heart function over DFP.
- Published
- 2013